Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC

October 1st 2020

Richard D. Kim, MD, discusses the potential of regorafenib plus nivolumab in patients with advanced colorectal cancer and the need for biomarkers to predict response to the regimen.

Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC

October 1st 2020

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer.

Palliative Care for Young Adults Is a Growing Reality in CRC

September 24th 2020

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

First-Line Pembrolizumab Improves Health-Related Quality of Life in DNA Repair-Deficient Metastatic Colorectal Cancer

September 19th 2020

As first-line therapy for patients with microsatellite instability-high and/or mismatch-repair deficient metastatic colorectal cancer, pembrolizumab improves quality of life compared with standard chemotherapy.

Preclinical Data Suggest Novel Molecule Enhances Immunotherapy Response in CRC

September 17th 2020

Timothy Cragin Wang, MD, discusses the advent of immunotherapy and how it has revolutionized multiple areas of cancer treatment; however, the transformative potential of the modality has been mild in the field of colorectal cancer.

Dr. Farrington on the Importance of Patient Advocacy in CRC

September 16th 2020

Caroline Farrington, PhD, discusses the importance of patient advocacy in colorectal cancer.

Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal Cancer

September 15th 2020

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC

September 14th 2020

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Dr. Lenz on Optimal Sequencing Strategies in CRC

September 10th 2020

Heinz-Josef Lenz, MD, FACP, discusses optimal sequencing strategies for the treatment of patients with colorectal cancer.

Dr. Morris on the Design of the COBRA Trial in Stage II Colon Cancer

September 8th 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Dr. Halfdanarson on Investigational Agents in Driver-Negative CRC

September 3rd 2020

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 2nd 2020

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Later-Line Treatment Approaches Make Headway in CRC Management

September 2nd 2020

Axel Grothey, MD, explains the impact of tumor sidedness on treatment decisions and highlights novel later-line approaches that are under examination in colorectal cancer.

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

September 1st 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.

First Targeted Regimen Arrives for BRAF V600E-Mutant mCRC

September 1st 2020

The approval of encorafenib in combination with cetuximab advances the metastatic colorectal cancer paradigm, introducing a biomarker-specific regimen for patients with pretreated BRAF V600E–mutant disease.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31st 2020

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon Cancer

August 27th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Dr. Morris on the Role of Circulating Tumor DNA in Resected Colon Cancer

August 27th 2020

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Dr. Chu on the Impact of the KEYNOTE-177 Trial in mCRC

August 21st 2020

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in metastatic colorectal cancer.

Novel Combinations Dominate Later-Line Metastatic CRC Treatment Landscape

August 20th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses novel approaches under investigation in the later-line treatment of patients with CRC.